This revolutionary new immunotherapy will combine Intrommune’s disease-modifying treatment through its peanut oral mucosal immunotherapy (OMIT), with the rapid desensitization to allergens provided by Inimmune’s clinical stage proprietary immunotherapy.
UM Alumni Keep Health Care Local in Small-Town Montana
Working every day with your best friend would be a dream come true for some people. Getting to work with your best friend to provide a vital service to your hometown community would make it even more special. For University of Montana alums Stacy Conrow-Ververis and Laurel Chambers that dream is a reality.
Opio Receives $1.5M Award from National Institutes of Health
Opio Connect, Inc., a technology company dedicated to helping Opioid Treatment Programs (OTPs) expand access to treatment, has received a $1.5 million award from the National Institute of Drug Abuse (NIDA), a division of the National Institutes of Health (NIH).
Montana State receives $26.7 million grant for facility to test and promote quantum technology
With a new $26.7 million grant from the U.S. Air Force, Montana State University will establish a facility with the mission of moving advanced quantum technology applications in cybersecurity, communications technology and national defense from concept and testing to market.
Montana State receives $6 million to enhance its research impact
With new funding from the U.S. National Science Foundation, research conducted at Montana State University will have more opportunities to be translated into products and solutions with extended real-life impact. MSU was announced last week as one of 18 teams nationwide to receive funding through the NSF’s new Accelerating Research Translation, or ART, program. The cooperative agreement will provide $6 million in support over the next four years.
$4 Million Award Funds UM Biomedical Entrepreneurship and Innovation Hub
The University of Montana recently earned a four-year, $4 million Research Evaluation and Commercialization Hub (REACH) award from the National Institutes of Health. The award will establish the L.S. Skaggs Institute for Health Innovation–Research Evaluation and Commercialization Hub (SIHI-REACH).
Tonix Pharmaceuticals Completes Clinical Stage of Phase 3 RESILIENT Study of TNX-102 SL for the Management of Fibromyalgia
A total of 457 patients were enrolled in this multi-site study in the U.S. Topline results are expected in late December 2023. If successful, it is expected to be the final, well-controlled efficacy trial required for submission of a New Drug Application (NDA) for approval by the U.S. Food and Drug Administration (FDA).
FYR Diagnostics Welcomes Dr. Kirk Tanner and Dr. Andy Hill to its Scientific Advisory Board
FYR Diagnostics, a pioneering company in the development of liquid biopsy technologies, is thrilled to announce the addition of Dr. Kirk Tanner and Dr. Andy Hill to its Scientific Advisory Board.
University of Montana receives $12.3M National Institutes of Health contract for work on TB vaccine
A vaccine for tuberculosis exists, but TB is still the 2nd leading infectious killer in the world after Covid-19, according to the World Health Organization. With a $12.3 million contract from the National Institutes of Health, researchers at the University of Montana are hoping to improve the vaccine for TB and positively influence global health.
Tonix Pharmaceuticals Announces Enrollment Initiated in Mass General Brigham Phase 2 Investigator-Initiated Study of TNX-1900 (Intranasal Potentiated Oxytocin) for Bone Health in Children with Autism Spectrum Disorder
Children with Autism Spectrum Disorder are at Risk for Low Bone Density. Preliminary Data Suggest that the Administration of Oxytocin May Favorably Impact Bone Formation and Strength